Adicet Bio, Inc.

Healthcare · Biotechnology · United States

Last price 3.42 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 36.81M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company’s lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in ...